


Have you seen the Dutch data?

BD SurePath™ Liquid-based Pap Test

It's confirmed — BD SurePath™ is the right choice


Independent analysis shows BD SurePath™ Liquid-based Pap Test finds more disease, earlier

BD SurePath™ was associated with a statistically significant increase in the detection of CIN2+¹



SS = Statistically significant, NSS = Not statistically significant
*Adjusted for year, age, screen region and socioeconomic status

BD SurePath™ was associated with lower interval cervical cancer rates²



The unadjusted cumulative incidence of cervical cancer is significantly lower 1, 3, 4 and 5 years after a negative primary BD SurePath™ smear than after a conventional smear.



BD SurePath™ Liquid-based Pap Test

Have you seen the Dutch data?

New national screening data on comparative performance for cervical disease detection

Visit ReachMD.com to hear key opinion leaders discuss a recently published study that evaluates the impact of liquid-based cytology on the detection of CIN
ReachMD.com/programs/advances-in-womens-health



About the analysis

The Dutch cervical cancer screening program invites women, age 30 to 60, every five years for primary cytology and triage to cytology or to HPV testing. An independent analysis was performed of cervical cancer incidence after a negative Pap smear to study the effect of the increasing use of liquid-based cytology (LBC) tests on outcomes, comparing BD SurePath™ Liquid-based Pap Test and ThinPrep® with conventional cytology.

- Data was drawn from the national registry in the Netherlands with more than 6 million data points
- Negative smears from initial screening were followed for subsequent cervical cancer detection within six years in the intervening years 2000–2012
- The cumulative incidence rate for cervical cancer and adjusted relative hazard ratio for a negative cytology result were determined for the two LBC types in comparison to conventional cytology

About Erasmus University Rotterdam:

- Top-ranked public university located in Rotterdam, Netherlands
- Erasmus MC is the largest and one of the foremost academic medical centers in the Netherlands

This independent analysis was conducted by Erasmus University Medical Center for the Department of Public Health, Rotterdam, Netherlands. The authors did not ask for or receive any input or compensation from BD.

1 Rozemeijer K, Penning C, Siebers AG, et al. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. *Cancer Causes Control*. 2015 Oct 12. [Epub ahead of print]

2 Rozemeijer K. Cervical cancer incidence after a negative smear: comparing SurePath and ThinPrep with conventional cytology. Poster presented at the 15th World Congress of the International Federation of Cervical Pathology and Colposcopy; May 26-30, 2104; London.



BD Lifesciences

11 rue Aristide Bergès
38800 Le Pont de Claix
France
Tel : 33.476.68.36.36
bd.com/ds